Polarean Imaging PLC

Polarean Imaging receives system order from Canadian children’s hospital

The order for the 9820 Xenon Polariser system will take the total number of Polarean's polarisers installed or on order to 24

Xenon element
The 9820 provides hyperpolarised Xenon for use in magnetic resonance studies

Polarean Imaging PLC (LON:POLX) has received a research unit order for its 9820 Xenon Polariser system from The Hospital for Sick Children (SickKids) in Toronto.

The order for the 9820, which provides hyperpolarised Xenon for use in magnetic resonance studies, will, once received, take the total number of polarisers installed or on order to 24.

READ: Polarean Imaging to receive third tranche of research grant

The system will also help to expand SickKids' ongoing paediatric research programme using hyperpolarised gas imaging.

The hospital currently has an earlier model of Polarean’s polariser, which has recently been upgraded.

"We are very happy to extend our long-standing relationship with SickKids Hospital in Toronto who work tirelessly on the paediatric applications of hyperpolarised xenon imaging for this important patient population", said Richard Hullihen, Polarean’s chief executive.

In early trading on Wednesday, Polarean's shares were steady at 15p.

Quick facts: Polarean Imaging PLC

Price: £0.24

Market: AIM
Market Cap: £27.64 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...



Full interview: Polarean Imaging begins enrolment for phase III clinical...

Polarean Imaging PLC's (LON:POLX) Richard Hullihen tells Proactive London's Andrew Scott they're on track to complete recruitment to their phase III clinical trial by the end of the current quarter following the enrolment of the first patient at the third site. The company’s drug-device...

2 weeks, 3 days ago


Phase III Clinical Trials update

2 weeks, 4 days ago

Total Voting Rights

3 weeks, 2 days ago

Holding(s) in Company

3 weeks, 3 days ago

Holding(s) in Company

3 weeks, 3 days ago

Holding(s) in Company

3 weeks, 4 days ago

Result of AGM

4 weeks, 1 day ago

Exercise of Warrants

4 weeks, 2 days ago

2 min read